已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study

美罗华 医学 狼疮性肾炎 内科学 胃肠病学 临床终点 安慰剂 中性粒细胞减少症 不利影响 环磷酰胺 免疫学 随机对照试验 化疗 淋巴瘤 病理 疾病 替代医学
作者
Brad H. Rovin,Richard Furie,Kevin Latinis,R. John Looney,Fernando C. Fervenza,Jorge Sánchez‐Guerrero,Romeo Maciuca,David Zhang,Jay Garg,Paul Brunetta,Gerald B. Appel
出处
期刊:Arthritis & Rheumatism [Wiley]
卷期号:64 (4): 1215-1226 被引量:1282
标识
DOI:10.1002/art.34359
摘要

To evaluate the efficacy and safety of rituximab in a randomized, double-blind, placebo-controlled phase III trial in patients with lupus nephritis treated concomitantly with mycophenolate mofetil (MMF) and corticosteroids.Patients (n = 144) with class III or class IV lupus nephritis were randomized 1:1 to receive rituximab (1,000 mg) or placebo on days 1, 15, 168, and 182. The primary end point was renal response status at week 52.Rituximab depleted peripheral CD19+ B cells in 71 of 72 patients. The overall (complete and partial) renal response rates were 45.8% among the 72 patients receiving placebo and 56.9% among the 72 patients receiving rituximab (P = 0.18); partial responses accounted for most of the difference. The primary end point (superior response rate with rituximab) was not achieved. Eight placebo-treated patients and no rituximab-treated patients required cyclophosphamide rescue therapy through week 52. Statistically significant improvements in serum complement C3, C4, and anti-double-stranded DNA (anti-dsDNA) levels were observed among patients treated with rituximab. In both treatment groups, a reduction in anti-dsDNA levels greater than the median reduction was associated with reduced proteinuria. The rates of serious adverse events, including infections, were similar in both groups. Neutropenia, leukopenia, and hypotension occurred more frequently in the rituximab group.Although rituximab therapy led to more responders and greater reductions in anti-dsDNA and C3/C4 levels, it did not improve clinical outcomes after 1 year of treatment. The combination of rituximab with MMF and corticosteroids did not result in any new or unexpected safety signals.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
MchemG应助Karol采纳,获得10
1秒前
1秒前
miles发布了新的文献求助10
1秒前
Rondab应助lzm采纳,获得10
2秒前
CipherSage应助十四采纳,获得10
3秒前
稳重怀蕊发布了新的文献求助10
4秒前
天天快乐应助马尔斯采纳,获得10
5秒前
兜里全是糖完成签到,获得积分10
6秒前
8秒前
一介尘埃完成签到 ,获得积分10
8秒前
CodeCraft应助mmmmm采纳,获得10
10秒前
wang发布了新的文献求助10
10秒前
斯文的难破完成签到 ,获得积分10
11秒前
12秒前
温柔烧鹅发布了新的文献求助10
13秒前
14秒前
15秒前
冷风完成签到 ,获得积分10
17秒前
马尔斯发布了新的文献求助10
17秒前
pumpkin完成签到,获得积分10
18秒前
古道小七完成签到,获得积分10
19秒前
Ramer556发布了新的文献求助10
20秒前
pumpkin发布了新的文献求助10
21秒前
领导范儿应助温柔烧鹅采纳,获得10
29秒前
LJC完成签到,获得积分10
30秒前
Ramer556完成签到,获得积分10
32秒前
32秒前
32秒前
负责怀莲发布了新的文献求助10
33秒前
夏夏完成签到 ,获得积分10
38秒前
38秒前
bkagyin应助hhllhh采纳,获得10
45秒前
顾矜应助魁梧的人达采纳,获得10
46秒前
Ava应助mw采纳,获得10
48秒前
49秒前
50秒前
所所应助zephyr采纳,获得30
51秒前
负责怀莲发布了新的文献求助10
52秒前
52秒前
儒雅南风发布了新的文献求助10
53秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989868
求助须知:如何正确求助?哪些是违规求助? 3531994
关于积分的说明 11255752
捐赠科研通 3270793
什么是DOI,文献DOI怎么找? 1805053
邀请新用户注册赠送积分活动 882215
科研通“疑难数据库(出版商)”最低求助积分说明 809208